ACSL4 and Osteosarcoma Progression
Author Information
Author(s): Li Xiaofeng, Chen Qianfen, Zhao Duo, Tan Jianshi, Liao Rongbo, Gu Yurong, Zhu Jinwei, Zhang Huying, Xie Jian, Chen Lu
Primary Institution: The Second Affiliated Hospital of Guangxi Medical University
Hypothesis
ACSL4 regulates osteosarcoma progression by modulating the TGF-β/Smad2 signaling pathway.
Conclusion
ACSL4 is a promising therapeutic target for osteosarcoma patients as its knockdown suppresses tumor growth and malignant behaviors.
Supporting Evidence
- ACSL4 was significantly up-regulated in osteosarcoma tissues compared to para-carcinoma tissues.
- Knockdown of ACSL4 suppressed cell proliferation and induced apoptosis in osteosarcoma cell lines.
- ACSL4 knockdown impaired tumor growth in a xenograft mouse model.
- ACSL4 regulates the phosphorylation of Smad2, which is involved in the TGF-β signaling pathway.
Takeaway
This study found that a protein called ACSL4 helps cancer cells grow in a type of bone cancer called osteosarcoma, and blocking it could help treat the disease.
Methodology
The study used immunohistochemistry, qPCR, loss-of-function experiments, and a xenograft mouse model to investigate the role of ACSL4 in osteosarcoma.
Limitations
The exact mechanisms by which ACSL4 regulates EMT in osteosarcoma and its effects on ferroptosis remain unclear.
Participant Demographics
The study included 61 osteosarcoma patients with varying tumor stages.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website